124 related articles for article (PubMed ID: 37690543)
1. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients.
Esdaille AR; Karam JA; Master VA; Spiess PE; Raman JD; Sharma P; Shapiro DD; Das A; Sexton WJ; Zemp L; Patil D; Allen GO; Matin SF; Wood CG; Abel EJ
Urology; 2023 Dec; 182():168-174. PubMed ID: 37690543
[TBL] [Abstract][Full Text] [Related]
2. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
Gershman B; Moreira DM; Boorjian SA; Lohse CM; Cheville JC; Costello BA; Leibovich BC; Thompson RH
Eur Urol; 2016 Jan; 69(1):84-91. PubMed ID: 26044802
[TBL] [Abstract][Full Text] [Related]
4. Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012.
Jackson BL; Fowler S; Williams ST;
BJU Int; 2015 Dec; 116(6):905-10. PubMed ID: 25098910
[TBL] [Abstract][Full Text] [Related]
5. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
7. A Contemporary Analysis of the 30-day Morbidity and Mortality Associated With Cytoreductive Nephrectomy.
May DN; Hill H; Matrana MR; Lata-Arias K; Canter DJ
Urology; 2021 Jan; 147():186-191. PubMed ID: 33203521
[TBL] [Abstract][Full Text] [Related]
8. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients.
Palumbo C; Knipper S; Dzyuba-Negrean C; Pecoraro A; Rosiello G; Tian Z; Shariat SF; Simeone C; Briganti A; Saad F; Berruti A; Antonelli A; Karakiewicz PI
J Geriatr Oncol; 2020 May; 11(4):718-723. PubMed ID: 31257163
[TBL] [Abstract][Full Text] [Related]
9. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
[TBL] [Abstract][Full Text] [Related]
10. Hospital volume and short-term outcomes after cytoreductive nephrectomy.
Xia L; Strother MC; Taylor BL; Chelluri RR; Pulido JE; Guzzo TJ
J Surg Oncol; 2018 Jun; 117(7):1589-1596. PubMed ID: 29575038
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for the development of postoperative complications in patients with metastatic kidney cancer treated with cytoreductive nephrectomy.
Hernández-Pañeda H; Garza-Gangemi AM; Manzanilla-Romero HH; Hernández-Gaytán CA; Gabilondo-Navarro F; Rodríguez-Covarrubias F
Cir Cir; 2021; 89(5):632-637. PubMed ID: 34665165
[TBL] [Abstract][Full Text] [Related]
12. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
[TBL] [Abstract][Full Text] [Related]
13. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
14. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Silagy AW; Kotecha RR; Weng S; Holmes A; Singla N; Mano R; Attalla K; Weiss KL; DiNatale RG; Patil S; Coleman JA; Motzer RJ; Russo P; Voss MH; Hakimi AA
Cancer; 2021 Nov; 127(21):3946-3956. PubMed ID: 34286865
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
16. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
[TBL] [Abstract][Full Text] [Related]
17. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
18. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience.
Abel EJ; Thompson RH; Margulis V; Heckman JE; Merril MM; Darwish OM; Krabbe LM; Boorjian SA; Leibovich BC; Wood CG
Eur Urol; 2014 Sep; 66(3):584-92. PubMed ID: 24262104
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
20. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]